Exploring the possibility of tumor growth after discontinuation of axitinib/axitinib

Axitinib/Axitinib is a targeted therapy drug mainly used for the treatment of advanced renal cell carcinoma. It prevents tumor blood supply and growth by inhibiting vascular endothelial growth factor receptor (VEGFR). In clinical practice, many patients have effective tumor control after receiving axitinib treatment, but once the drug is stopped, the situation faced by the patients becomes complicated.

First, understanding the mechanism of action of axitinib is critical to predicting response after discontinuation of the drug. This drug achieves tumor control by inhibiting the proliferation and angiogenesis of tumor cells. If a patient has achieved good results during use, there may be a risk of tumor recurrence after discontinuation of treatment, because in the absence of inhibitory signals, tumor cells may start to proliferate again.

Secondly, the biological characteristics of the tumor, individual patient differences, and previous treatment history will all affect the response after drug withdrawal. Some patients are able to maintain a longer progression-free survival after stopping treatment, which is usually related to the characteristics of the tumor and its dependence on external factors; while other patients may experience rapid tumor recurrence within a short period of time. Therefore, it cannot simply be assumed that drug withdrawal will inevitably lead to rapid tumor growth.

In addition, clinical studies also show that after stopping axitinib, the patient's therapeutic effect can still be guaranteed to a certain extent through regular monitoring and timely intervention. Some doctors recommend closely observing changes in the patient's condition after stopping the drug and deciding whether to restart treatment or use other therapies based on the specific situation.

Finally, when patients decide to discontinue medication, they should fully communicate with their doctors to understand the monitoring plan and potential risks after discontinuation. At the same time, maintaining a healthy lifestyle and a positive attitude can also help enhance the body's resistance and reduce the risk of tumor recurrence.

References:https://www.plainlanguagesummaries.com/plain-language-summary-looking-at-how-long-side-effects-last-after-stopping-axitinib-treatment-in-people-with-advanced-renal-cell-carcinoma/